{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:03:31Z","timestamp":1772244211614,"version":"3.50.1"},"reference-count":25,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR Research Partnership Award\u2013Liver Disease","award":["NIHR155530"],"award-info":[{"award-number":["NIHR155530"]}]}],"content-domain":{"domain":["openresearch.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["NIHR Open Res"],"abstract":"<ns3:p>Background The prevalence of liver disease is rising in the United Kingdom (UK), with obesity underpinning surging metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD is associated with an increased cardiometabolic risk, particularly when co-existing with type 2 diabetes. Progression to metabolic dysfunction-associated steatohepatitis (MASH) with hepatic fibrosis represents a clinical milestone strongly linked to serious liver disease and mortality. Therefore, clinically meaningful and sustained weight loss (\u226510%) is a primary therapeutic target for patients with MASLD. Unfortunately, this is difficult for most people who adopt traditional lifestyle approaches. However, new obesity pharmacotherapies hold promise in MASLD, given their ability to produce dramatic weight loss (10\u201325%) and improve cardiometabolic health. Questions remain about the ability of these agents to improve liver fibrosis and patient-reported outcomes\/quality of life in patients with advanced liver disease. Methods Led from the Midlands (UK) but with national representation, we developed a network of stakeholders (clinicians, academics, third-sector, industry, and PPIE representatives) with an interest in obesity-related liver diseases. This network was called the Midlands Liver Research Alliance (MLRA), which sought to 1) establish a PPIE stakeholder network, 2) identify research priorities, and 3) map the network infrastructure and expertise. Health inequalities within liver disease are a core priority within the MLRA. Results The MLRA developed a large PPIE stakeholder network in collaboration with other local liver partnerships. These networks facilitated the identification of key research priorities that led to three NIHR funding applications. Priorities centered around: 1) the importance of patient-centered outcomes in obesity-related liver disease research; 2) the potential of glucagon-like peptide 1 (GLP-1)-based obesity pharmacotherapy in alcohol use disorder; and 3) early identification and management of liver disease in primary care\/community. Conclusions The MLRA has created a multidisciplinary hub of research expertise in obesity-related liver disease. This foundation provides a springboard for research activities in this area.<\/ns3:p>","DOI":"10.3310\/nihropenres.13784.1","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T07:00:06Z","timestamp":1733986806000},"page":"75","update-policy":"https:\/\/doi.org\/10.3310\/nihropenres.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities"],"prefix":"10.3310","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-9173","authenticated-orcid":false,"given":"James","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guruprasad","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Herring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Papamargaritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Hulley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1335-1347","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): a systematic review.","volume":"77","author":"Z Younossi","year":"2023","journal-title":"Hepatology."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"944-56","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease.","volume":"9","author":"H Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"196-205","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach.","volume":"13","author":"M Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","author":"E Melson","year":"2024","journal-title":"Int J Obes (Lond)."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"989-1002","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"J Wilding","year":"2021","journal-title":"N Engl J Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1414-25","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.","volume":"325","author":"D Rubino","year":"2021","journal-title":"JAMA."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"514-26","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor agonist retatrutide for obesity \u2014 a phase 2 trial.","volume":"389","author":"A Jastreboff","year":"2023","journal-title":"N Engl J Med."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"299-310","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.","volume":"391","author":"R Loomba","year":"2024","journal-title":"N Engl J Med."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"561-2","DOI":"10.1080\/08039488.2016.1176252","article-title":"Glucagon-like peptide-1 (GLP-1) analogues: a potential new treatment for alcohol use disorder?","volume":"70","author":"A Fink-Jensen","year":"2016","journal-title":"Nord J Psychiatry."},{"key":"ref-10","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16946-4","article-title":"The association between alcohol intake and obesity in a sample of the Irish adult population, a cross-sectional study.","volume":"23","author":"S AlKalbani","year":"2023","journal-title":"BMC Public Health."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"39-52","DOI":"10.1016\/j.puhe.2023.10.035","article-title":"The independent and joint risks of alcohol consumption, smoking, and excess weight on morbidity and mortality: a systematic review and meta-analysis exploring synergistic associations.","volume":"226","author":"R Burton","year":"2024","journal-title":"Public Health."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1966-86","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"M Rinella","year":"2023","journal-title":"Hepatology."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"505-18","DOI":"10.1007\/s10198-020-01256-y","article-title":"Disease burden and economic impact of diagnosed Non-Alcoholic Steatohepatitis (NASH) in the United Kingdom (UK) in 2018.","volume":"22","author":"A Morgan","year":"2021","journal-title":"Eur J Health Econ."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"123-33","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"e916-23","DOI":"10.3399\/BJGP.2022.0094","article-title":"Liver disease management as routine work in primary care: a qualitative interview study to guide implementation.","volume":"72","author":"H Jarvis","year":"2022","journal-title":"Br J Gen Pract."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"e743-9","DOI":"10.3399\/bjgp18X699377","article-title":"GPs\u2019 experiences and perceptions of early detection of liver disease: a qualitative study in primary care.","volume":"68","author":"H Standing","year":"2018","journal-title":"Br J Gen Pract."},{"key":"ref-17","article-title":"Chief medical officer\u2019s annual report 2021 Health in coastal communities.","year":"2021"},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1004-16","DOI":"10.1016\/S2213-8587(15)00326-5","article-title":"Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management.","volume":"3","author":"N Sattar","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref-19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100597","article-title":"Patient-reported outcomes in NAFLD\/NASH clinical trials: a blind spot that needs addressing.","volume":"5","author":"E Sena","year":"2023","journal-title":"JHEP Rep."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1943-55","DOI":"10.1056\/NEJMoa1616338","article-title":"Aerobic or resistance exercise, or both, in dieting obese older adults.","volume":"376","author":"D Villareal","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"400-2","DOI":"10.1016\/S2468-1253(24)00009-8","article-title":"Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership.","volume":"9","author":"M Subhani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"ref-22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies.","volume":"14","author":"E Jerlhag","year":"2023","journal-title":"Front Pharmacol."},{"key":"ref-23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.","volume":"7","author":"M Klausen","year":"2022","journal-title":"JCI Insight."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1744-52","DOI":"10.14309\/ajg.0000000000000357","article-title":"Obesity is the most common risk factor for chronic liver disease: results from a risk stratification pathway using transient elastography.","volume":"114","author":"R Harris","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"774-85","DOI":"10.1002\/hep4.1678","article-title":"coreNASH: Multi-stakeholder consensus on core outcomes for decision making about nonalcoholic steatohepatitis treatment.","volume":"5","author":"E Clearfield","year":"2021","journal-title":"Hepatol Commun."}],"container-title":["NIHR Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:30:06Z","timestamp":1750386606000},"score":1,"resource":{"primary":{"URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":25,"URL":"https:\/\/doi.org\/10.3310\/nihropenres.13784.1","relation":{"has-review":[{"id-type":"doi","id":"10.3310\/nihropenres.14972.r35254","asserted-by":"subject"},{"id-type":"doi","id":"10.3310\/nihropenres.14972.r35250","asserted-by":"subject"},{"id-type":"doi","id":"10.3310\/nihropenres.14972.r35254","asserted-by":"object"},{"id-type":"doi","id":"10.3310\/nihropenres.14972.r35250","asserted-by":"object"}]},"ISSN":["2633-4402"],"issn-type":[{"value":"2633-4402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"Indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.3310\/nihropenres.14972.r35254, Dimitrios Koutoukidis, University of Oxford, Oxford, England, 26 May 2025, version 1, indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1#referee-response-35254","order":0,"name":"referee-response-35254","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.3310\/nihropenres.14972.r35250, Shelley Keating, The University of Queensland, St Lucia, 20 Jun 2025, version 1, indexed","URL":"https:\/\/openresearch.nihr.ac.uk\/articles\/4-75\/v1#referee-response-35250","order":1,"name":"referee-response-35250","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This project is funded by the National Institute for Health and Care Research (NIHR) under its NIHR Research Partnership Award\u2013Liver Disease (22\/72)\u2013NIHR155530. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}